DNA hypermethylated status and gene expression of PAX1/SOX1 in patients with colorectal carcinoma
Authors Huang J, Tan ZR, Yu J, Li H, Lv Q, Shao Y, Zhou H
Received 6 June 2017
Accepted for publication 14 July 2017
Published 26 September 2017 Volume 2017:10 Pages 4739—4751
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Ashok Kumar Pandurangan
Peer reviewer comments 2
Editor who approved publication: Dr Carlos E Vigil
Jin Huang,1,2 Zhi-Rong Tan,1,2 Jing Yu,1,2 He Li,1,2 Qiao-Li Lv,1,2 Ying-Ying Shao,3 Hong-Hao Zhou1,2
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, 2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, Hunan, 3Institute of Life Science, Chongqing Medical University, Yuzhong District, Chongqing, China
Background: Colorectal cancer (CRC) is a widespread and aggressive carcinoma with poor prognosis. Hypermethylation of specific gene promoters is an important mechanism of CRC. In this study, we investigated the hypermethylation of paired boxed gene 1 (PAX1) and sex-determining region Y-related high-mobility group box 1 (SOX1) genes in CRC tissues.
Methods: DNA methylation at cg2,09,07,471 PAX1 and cg0,66,75,478 SOX1 from 166 cancer tissues and 37 normal tissues from CRC patients were compared using datasets downloaded from The Cancer Genome Atlas. Quantitative methylation-specific polymerase chain reaction and assay of PAX1 and SOX1 were performed in dissected tumor and paracancerous tissues by surgery from 41 CRC patients. Quantitative reverse transcription polymerase chain reaction and immunohistochemistry assay were performed in both CRC and paired normal tissues to detect mRNA and protein expression, respectively.
Results: Methylation levels of PAX1/SOX1 genes were significantly higher in cancer tissues than in paired normal tissues. PAX1 and SOX1 genes were methylated in 28 (68.3%) of the 41 CRC samples but in 5 (12.2%) and 0 (0%) of the paired normal control samples (both P<0.001), respectively. Sensitivities and specificities of PAX1 methylation for the detection of cancer were 68.3% and 87.8%, respectively, whereas the corresponding values for SOX1 were 68.3% and 100%. However, the Kaplan–Meier analysis illustrated no significant difference in the overall survivals between patients with high and low methylation levels of SOX1 or PAX1 (P>0.5). In addition, the methylation level of PAX1/SOX1 was significantly higher in CRC patients with high TNM stage (TNM stage III/IV, 3.11±2.43) than those with low TNM stage (TNM stage I/II, 1.26±2.94, P<0.05). Relative RNA and protein expression levels of PAX1/SOX1 were both significantly lower in CRC tissues than in their paired normal tissue.
Conclusions: This study is the first analysis of the methylation of PAX1/SOX1, which may be new biomarkers for CRC screening.
Keywords: colorectal cancer, PAX1, SOX1, molecular biomarker, DNA methylation, epigenetic
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]